KYMR Relative Valuation
KYMR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KYMR is overvalued; if below, it's undervalued.
Historical Valuation
Kymera Therapeutics Inc (KYMR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 54.02 is considered Undervalued compared with the five-year average of -18.31. The fair price of Kymera Therapeutics Inc (KYMR) is between 48.72 to 66.83 according to relative valuation methord. Compared to the current price of 46.37 USD , Kymera Therapeutics Inc is Undervalued By 4.81%.
Relative Value
Fair Zone
48.72-66.83
Current Price：46.37
4.81%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.77
P/B
Median3y
3.28
Median5y
4.48
-7.62
FCF Yield
Median3y
-9.81
Median5y
-6.71
Competitors Valuation Multiple
The average P/S ratio for KYMR's competitors is 183.88, providing a benchmark for relative valuation. Kymera Therapeutics Inc Corp (KYMR) exhibits a P/S ratio of 54.02, which is -70.62% above the industry average. Given its robust revenue growth of 114.83%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Kymera Therapeutics Inc (KYMR) currently overvalued or undervalued?
What is Kymera Therapeutics Inc (KYMR) fair value?
How does KYMR's valuation metrics compare to the industry average?
What is the current P/B ratio for Kymera Therapeutics Inc (KYMR) as of Jul 19 2025?
What is the current FCF Yield for Kymera Therapeutics Inc (KYMR) as of Jul 19 2025?
What is the current Forward P/E ratio for Kymera Therapeutics Inc (KYMR) as of Jul 19 2025?